Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells

Eri Katsuyama, Hiroya Miyamoto, Tami Kobayashi, Yuiko Sato, Wu Hao, Hiroya Kanagawa, Atsuhiro Fujie, Toshimi Tando, Ryuichi Watanabe, Mayu Morita, Kana Miyamoto, Yasuo Niki, Hideo Morioka, Morio Matsumoto, Yoshiaki Toyama, Takeshi Miyamoto

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Formation of foreign body giant cells (FBGCs) occurs following implantation of medical devices such as artificial joints and is implicated in implant failure associated with inflammation or microbial infection. Two major macrophage subpopulations, M1 and M2, play different roles in inflammation and wound healing, respectively. Therefore, M1/M2 polarization is crucial for the development of various inflammation-related diseases. Here, we show that FBGCs do not resorb bone but rather express M2 macrophage-like wound healing and inflammation-terminating molecules in vitro. We also found that FBGC formation was significantly inhibited by inflammatory cytokines or infection mimetics in vitro . Interleukin-1 receptor-associated kinase-4 (IRAK4) deficiency did not alter osteoclast formation in vitro, and IRAK4-deficient mice showed normal bone mineral density in vivo. However, IRAK4-deficient mice were protected from excessive osteoclastogenesis induced by IL-1β in vitro or by LPS, an infection mimetic of Gram-negative bacteria, in vivo. Furthermore, IRAK4 deficiency restored FBGC formation and expression of M2 macrophage markers inhibited by inflammatory cytokines in vitro or by LPS in vivo. Our results demonstrate that osteoclasts and FBGCs are reciprocally regulated and identify IRAK4 as a potential therapeutic target to inhibit stimulated osteoclastogenesis and rescue inhibited FBGC formation under inflammatory and infectious conditions without altering physiological bone resorption.

Original languageEnglish
Pages (from-to)716-726
Number of pages11
JournalJournal of Biological Chemistry
Volume290
Issue number2
DOIs
Publication statusPublished - 2015 Jan 9

Fingerprint

Interleukin-1 Receptor-Associated Kinases
Foreign Body Giant Cells
Osteolysis
Osteoclasts
Macrophages
Bone
Inflammation
Osteogenesis
Wound Healing
Cytokines
Infection
Interleukin-1
Minerals
Bone Resorption
Gram-Negative Bacteria
Bacteria
Bone Density
Polarization
Joints
In Vitro Techniques

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells. / Katsuyama, Eri; Miyamoto, Hiroya; Kobayashi, Tami; Sato, Yuiko; Hao, Wu; Kanagawa, Hiroya; Fujie, Atsuhiro; Tando, Toshimi; Watanabe, Ryuichi; Morita, Mayu; Miyamoto, Kana; Niki, Yasuo; Morioka, Hideo; Matsumoto, Morio; Toyama, Yoshiaki; Miyamoto, Takeshi.

In: Journal of Biological Chemistry, Vol. 290, No. 2, 09.01.2015, p. 716-726.

Research output: Contribution to journalArticle

Katsuyama, E, Miyamoto, H, Kobayashi, T, Sato, Y, Hao, W, Kanagawa, H, Fujie, A, Tando, T, Watanabe, R, Morita, M, Miyamoto, K, Niki, Y, Morioka, H, Matsumoto, M, Toyama, Y & Miyamoto, T 2015, 'Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells', Journal of Biological Chemistry, vol. 290, no. 2, pp. 716-726. https://doi.org/10.1074/jbc.M114.568360
Katsuyama, Eri ; Miyamoto, Hiroya ; Kobayashi, Tami ; Sato, Yuiko ; Hao, Wu ; Kanagawa, Hiroya ; Fujie, Atsuhiro ; Tando, Toshimi ; Watanabe, Ryuichi ; Morita, Mayu ; Miyamoto, Kana ; Niki, Yasuo ; Morioka, Hideo ; Matsumoto, Morio ; Toyama, Yoshiaki ; Miyamoto, Takeshi. / Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells. In: Journal of Biological Chemistry. 2015 ; Vol. 290, No. 2. pp. 716-726.
@article{a7d802db4ced4fc89266c62f74a3247b,
title = "Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells",
abstract = "Formation of foreign body giant cells (FBGCs) occurs following implantation of medical devices such as artificial joints and is implicated in implant failure associated with inflammation or microbial infection. Two major macrophage subpopulations, M1 and M2, play different roles in inflammation and wound healing, respectively. Therefore, M1/M2 polarization is crucial for the development of various inflammation-related diseases. Here, we show that FBGCs do not resorb bone but rather express M2 macrophage-like wound healing and inflammation-terminating molecules in vitro. We also found that FBGC formation was significantly inhibited by inflammatory cytokines or infection mimetics in vitro . Interleukin-1 receptor-associated kinase-4 (IRAK4) deficiency did not alter osteoclast formation in vitro, and IRAK4-deficient mice showed normal bone mineral density in vivo. However, IRAK4-deficient mice were protected from excessive osteoclastogenesis induced by IL-1β in vitro or by LPS, an infection mimetic of Gram-negative bacteria, in vivo. Furthermore, IRAK4 deficiency restored FBGC formation and expression of M2 macrophage markers inhibited by inflammatory cytokines in vitro or by LPS in vivo. Our results demonstrate that osteoclasts and FBGCs are reciprocally regulated and identify IRAK4 as a potential therapeutic target to inhibit stimulated osteoclastogenesis and rescue inhibited FBGC formation under inflammatory and infectious conditions without altering physiological bone resorption.",
author = "Eri Katsuyama and Hiroya Miyamoto and Tami Kobayashi and Yuiko Sato and Wu Hao and Hiroya Kanagawa and Atsuhiro Fujie and Toshimi Tando and Ryuichi Watanabe and Mayu Morita and Kana Miyamoto and Yasuo Niki and Hideo Morioka and Morio Matsumoto and Yoshiaki Toyama and Takeshi Miyamoto",
year = "2015",
month = "1",
day = "9",
doi = "10.1074/jbc.M114.568360",
language = "English",
volume = "290",
pages = "716--726",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "2",

}

TY - JOUR

T1 - Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells

AU - Katsuyama, Eri

AU - Miyamoto, Hiroya

AU - Kobayashi, Tami

AU - Sato, Yuiko

AU - Hao, Wu

AU - Kanagawa, Hiroya

AU - Fujie, Atsuhiro

AU - Tando, Toshimi

AU - Watanabe, Ryuichi

AU - Morita, Mayu

AU - Miyamoto, Kana

AU - Niki, Yasuo

AU - Morioka, Hideo

AU - Matsumoto, Morio

AU - Toyama, Yoshiaki

AU - Miyamoto, Takeshi

PY - 2015/1/9

Y1 - 2015/1/9

N2 - Formation of foreign body giant cells (FBGCs) occurs following implantation of medical devices such as artificial joints and is implicated in implant failure associated with inflammation or microbial infection. Two major macrophage subpopulations, M1 and M2, play different roles in inflammation and wound healing, respectively. Therefore, M1/M2 polarization is crucial for the development of various inflammation-related diseases. Here, we show that FBGCs do not resorb bone but rather express M2 macrophage-like wound healing and inflammation-terminating molecules in vitro. We also found that FBGC formation was significantly inhibited by inflammatory cytokines or infection mimetics in vitro . Interleukin-1 receptor-associated kinase-4 (IRAK4) deficiency did not alter osteoclast formation in vitro, and IRAK4-deficient mice showed normal bone mineral density in vivo. However, IRAK4-deficient mice were protected from excessive osteoclastogenesis induced by IL-1β in vitro or by LPS, an infection mimetic of Gram-negative bacteria, in vivo. Furthermore, IRAK4 deficiency restored FBGC formation and expression of M2 macrophage markers inhibited by inflammatory cytokines in vitro or by LPS in vivo. Our results demonstrate that osteoclasts and FBGCs are reciprocally regulated and identify IRAK4 as a potential therapeutic target to inhibit stimulated osteoclastogenesis and rescue inhibited FBGC formation under inflammatory and infectious conditions without altering physiological bone resorption.

AB - Formation of foreign body giant cells (FBGCs) occurs following implantation of medical devices such as artificial joints and is implicated in implant failure associated with inflammation or microbial infection. Two major macrophage subpopulations, M1 and M2, play different roles in inflammation and wound healing, respectively. Therefore, M1/M2 polarization is crucial for the development of various inflammation-related diseases. Here, we show that FBGCs do not resorb bone but rather express M2 macrophage-like wound healing and inflammation-terminating molecules in vitro. We also found that FBGC formation was significantly inhibited by inflammatory cytokines or infection mimetics in vitro . Interleukin-1 receptor-associated kinase-4 (IRAK4) deficiency did not alter osteoclast formation in vitro, and IRAK4-deficient mice showed normal bone mineral density in vivo. However, IRAK4-deficient mice were protected from excessive osteoclastogenesis induced by IL-1β in vitro or by LPS, an infection mimetic of Gram-negative bacteria, in vivo. Furthermore, IRAK4 deficiency restored FBGC formation and expression of M2 macrophage markers inhibited by inflammatory cytokines in vitro or by LPS in vivo. Our results demonstrate that osteoclasts and FBGCs are reciprocally regulated and identify IRAK4 as a potential therapeutic target to inhibit stimulated osteoclastogenesis and rescue inhibited FBGC formation under inflammatory and infectious conditions without altering physiological bone resorption.

UR - http://www.scopus.com/inward/record.url?scp=84920895931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920895931&partnerID=8YFLogxK

U2 - 10.1074/jbc.M114.568360

DO - 10.1074/jbc.M114.568360

M3 - Article

C2 - 25404736

AN - SCOPUS:84920895931

VL - 290

SP - 716

EP - 726

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 2

ER -